国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產品 » 穩定細胞系 » Human Recombinant Calcitonin Receptor Stable Cell Line
CHO-K1/CT/Gα15 Stable Cell Line

Figure 1: Calcitonin-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CT/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with CT agonist, calcitonin. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of calcitonin (mean ± SEM, n = 3). The EC50 of calcitonin on CHO-K1/CT/Gα15 cells was 18.88 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50 -X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.

CHO-K1/CT/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP mobilization upon treatment with calcitonin in CHO-K1/CT/Gα15 cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CT/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Varioskan, Thermo Fisher). The EC50 of calcitonin was 0.27 nM.

CHO-K1/CT/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human calcitonin receptor (CT) on the surface and contain high levels of G protein Gαq and Gαs to couple with the receptor in downstream signaling pathways.
M00320
詢價

聯系我們
Product Description Recombinant CHO-K1 cells stably overexpress human calcitonin receptor (CT) on the surface and contain high levels of G protein Gαq and Gαs to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/CT/Gα15 Stable Cell Line
  • CHO-K1/CT/Gα15 Stable Cell Line

    Figure 1: Calcitonin-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CT/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with CT agonist, calcitonin. The intracellular calcium change was measured by FLIPRTETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of calcitonin (mean ± SEM, n = 3). The EC50 of calcitonin on CHO-K1/CT/Gα15 cells was 18.88 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC50 -X)*Hill Slope))
    X is the logarithm of concentration. Y is the response.
    Y is RFU and starts at Bottom and goes to Top along a sigmoid curve.

  • CHO-K1/CT/Gα15 Stable Cell Line
  • CHO-K1/CT/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP mobilization upon treatment with calcitonin in CHO-K1/CT/Gα15 cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CT/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Varioskan, Thermo Fisher). The EC50 of calcitonin was 0.27 nM.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級的網站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 安溪县| 乌兰浩特市| 南安市| 都安| 林口县| 荆州市| 驻马店市| 日喀则市| 东乌| 六枝特区| 和静县| 临漳县| 耿马| 长沙县| 淳化县| 大方县| 顺昌县| 诸城市| 河间市| 内丘县| 太康县| 张家界市| 黄浦区| 正安县| 清远市| 安岳县| 长宁区| 广灵县| 波密县| 荣昌县| 屏山县| 宜兰市| 乌拉特后旗| 治多县| 仙居县| 章丘市| 昌乐县| 青铜峡市| 溧水县| 大城县| 泾阳县|